Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

This study is testing a combination of two drugs — atezolizumab (immunotherapy) and bevacizumab (anti-blood vessel drug) — together with targeted radiation (stereotactic body radiotherapy or SBRT) for people with advanced liver cancer that cannot be surgically removed. **You may be eligible if...** - You are between 19 and 80 years old - You have been diagnosed with hepatocellular carcinoma (liver cancer) - Your cancer cannot be operated on (advanced/inoperable) - Your liver function is relatively preserved (Child-Pugh class A) - Your general health score is good (ECOG 0-1) - Your tumor size is appropriate for targeted radiation **You may NOT be eligible if...** - You have cancer that has spread to the brain - You had another cancer (other than liver cancer) in the past 5 years - You have untreated or high-risk esophageal varices that could bleed - You have serious uncontrolled medical conditions - You have had a liver transplant - You have autoimmune liver disease Talk to your doctor to see if this trial is right for you.